Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTKenya: Arterolane-piperaquine +/- Mefloquine vs AL for Malaria
NCT03452475Phase 3Completed
- Sponsor
- University of Oxford
- Start
- Mar 2018
- Primary completion
- Jun 2019
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Arterolane and piperaquine in Malaria (3 arms), sponsored by University of Oxford. Primary endpoint: Adequate Clinical and Parasitological Response at 42 days. Started Mar 2018; status: completed.
02
Drugs
Arterolanepiperaquine
03
Conditions
Malaria
Beyond the preview
Go deeper on NCT03452475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03452475.